News stories about Strongbridge Biopharma (NASDAQ:SBBP) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.9902215619421 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Strongbridge Biopharma (SBBP) PT Set at $14.00 by Cantor Fitzgerald (americanbankingnews.com)
- Strongbridge Biopharma (SBBP) Lowered to “Buy” at BidaskClub (americanbankingnews.com)
- Strongbridge Bio (SBBP) Doses First Four Patients in LOGICS, Second Global Phase 3 Study of RECORLEV in Endogenous Cushing’s Syndrome (streetinsider.com)
- Strongbridge Biopharma doses first four patients in LOGICS, a second global Phase 3 study of RECORLEV in endogenous CS (seekingalpha.com)
- $3.25 Million in Sales Expected for Strongbridge Biopharma plc (SBBP) This Quarter (americanbankingnews.com)
Strongbridge Biopharma stock traded down $0.20 during mid-day trading on Thursday, hitting $8.30. 178,996 shares of the company’s stock were exchanged, compared to its average volume of 310,366. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. The company has a market capitalization of $386.83, a price-to-earnings ratio of -5.72 and a beta of 0.99. Strongbridge Biopharma has a 1-year low of $3.50 and a 1-year high of $9.25.
Several analysts recently issued reports on the company. BidaskClub lowered Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Cantor Fitzgerald set a $14.00 price objective on Strongbridge Biopharma and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Strongbridge Biopharma in a report on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $12.81.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.